Aquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Leerink Partners

Leerink Partners reiterated their outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report released on Monday, Benzinga reports. They currently have a $12.00 target price on the stock, up from their prior target price of $10.00.

AQST has been the subject of several other research reports. HC Wainwright raised their target price on Aquestive Therapeutics from $9.00 to $10.00 and gave the company a buy rating in a research note on Monday. JMP Securities reissued a market outperform rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Monday, August 12th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $8.67.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $4.79 on Monday. The firm’s 50-day moving average is $4.29 and its 200-day moving average is $3.68. The company has a market cap of $436.08 million, a P/E ratio of -11.33 and a beta of 2.84. Aquestive Therapeutics has a 1 year low of $1.25 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the firm earned ($0.10) EPS. As a group, sell-side analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth $27,000. PFG Investments LLC boosted its holdings in Aquestive Therapeutics by 22.9% during the second quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock valued at $153,000 after acquiring an additional 11,000 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at about $54,000. Financial Advocates Investment Management increased its stake in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the period. Finally, Lazard Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.